Antioxidant activity and inhibition of human cancer cells by the herbal product, ARCOMIG
Article
Aregullin, M, Berry, JP, Cadena, L. (2006). Antioxidant activity and inhibition of human cancer cells by the herbal product, ARCOMIG
. 6(2), 229-234. 10.3923/jms.2006.229.234
Aregullin, M, Berry, JP, Cadena, L. (2006). Antioxidant activity and inhibition of human cancer cells by the herbal product, ARCOMIG
. 6(2), 229-234. 10.3923/jms.2006.229.234
To assess the potential efficacy of this product, we investigated two relevant biological activities of the ARCOMIG preparation. Specifically, ARCOMIG was evaluated for inhibition of a representation of human cancer cell-lines, including colon (HT29), ovarian (SK-OV-3), mammary (SK-BR-3), renal (A498) and lung adenocarcinoma, as well as glioblastoma (U251) and lymphocytic leukemia (CEM), lines. In addition, ARCOMIG was assessed by spectrophotometric techniques for both in vitro antioxidant activity, specifically using the model free-radical, 1,1,-diphenyl-2-picrylhydrazyl (DPPH) and for inhibition of intracellular reactive oxygen species (ROSs), specifically using the fluorescent indicator, 2′,7′-dichlorofluorescin (DCFH). Results of these assays demonstrate that ARCOMIG moderately inhibited all cancer lines tested and was particularly active with respect to a lymphocytic leukemia line. Moreover, at concentrations well below those for which cytotoxicity was observed, ARCOMIG rapidly and potently reduced the free radical, DPPH, as well as inhibiting the intracellular production of ROSs in human colon cells. When compared to the well-recognized dietary antioxidant, resveratrol, the results suggest that the antioxidant activity of ARCOMIG may equal or even surpass the activity of this compound. Taken together, these findings are consistent with purported clinical efficacy of ARCOMIG, however, further studies are clearly needed to elucidate the putative health benefits of this herbal product.
